Global Nivolumab Drugs Market Size, Share, and Trends Analysis Report, By Indication (Non-Small Cell Lung Cancer (NSCLC), Melanoma, Malignant Pleural Mesothelioma, Renal Cell Carcinoma (RCC), Classical Hodgkin Lymphoma (cHL), Squamous Cell Carcinoma of the Head and Neck (SCCHN), and Others), and By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) Forecast Period (2022-2028)

The global nivolumab drugs market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). The generic name of Opdivo is Nivolumab, a targeted treatment medication. Nivolumab is currently approved for unresectable or metastatic melanoma, metastatic non-small cell lung cancer (NSCLC), advanced renal cell cancer, classical Hodgkin’s lymphoma (cHL), and recurrent or metastatic squamous cell carcinoma, among other indications.

 

During the forecast period, the market for nivolumab pharmaceuticals is likely to be driven by a rising incidence of NSCLC. According to the American Cancer Society, about 235,760 new instances of lung cancer were diagnosed and 131,880 people died from lung cancer in the US alone in 2020. NSCLC accounts for around 84% of this total lung cancer cases.  Additionally, during the projection period, approval of nivolumab for newer indications is also expected to propel market growth.

 

The market players are also contributing significantly to the growth of the market by the adoption of various strategies including mergers and acquisitions, geographical expansion, partnerships, collaborations, and new product launches, in order to stay competitive in the market. For instance-

 

• In December 2021, Ono Pharmaceutical Co., Ltd. and Bristol-Myers Squibb K.K. have announced that Opdivo Intravenous Infusion, an anti-human PD-1 monoclonal antibody, has received supplemental approval in Japan for expanded use in the treatment of cancer.
• In February 2021, the Taiwan Food and Drug Administration (TFDA) approved Opdivo Intravenous Infusion 20 mg, 100 mg injection for additional indications of the first-line treatment of advanced or recurrent NSCLC with no EGFR or ALK genomic tumor aberrations.
• In January 2021, the combination of nivolumab (Opdivo, Bristol-Myers Squibb Co.) and cabozantinib (Cabometyx, Exelixis) has been approved by the USFDA as a first-line treatment for patients with advanced renal cell carcinoma (RCC).

 

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Indication
  • By Distribution Channel
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

· Competitive Landscape– Ono Pharmaceutical Co., Ltd., and Bristol Myers Squibb, among others.

 

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

 

Global Nivolumab Drugs Market Report by Segment

By Indication

• Non-Small Cell Lung Cancer (NSCLC)
• Melanoma, Malignant Pleural Mesothelioma
• Renal Cell Carcinoma (RCC)
• Classical Hodgkin Lymphoma (cHL)
• Squamous Cell Carcinoma of the Head and Neck (SCCHN)
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Nivolumab Drugs Market Report by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa